Immunogenicity

Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

Retrieved on: 
Tuesday, January 9, 2024

Transgene and NEC expect to present additional immunological and clinical data from the Phase I trial at a scientific conference in the first half of 2024.

Key Points: 
  • Transgene and NEC expect to present additional immunological and clinical data from the Phase I trial at a scientific conference in the first half of 2024.
  • We are looking forward to continuing to treat patients with our individualized cancer vaccine TG4050.
  • Masamitsu Kitase, Corporate SVP, Head of Healthcare and Life Sciences Division, NEC Corporation, commented: "Transgene has been our trusted partner in developing our joint neoantigen asset TG4050.
  • *Ottensmeier et al., "Safety and Immunogenicity of TG4050: a personalized cancer vaccine in head and neck carcinoma" ASCO 2023, June 6, 2023, Poster presentation

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

Retrieved on: 
Wednesday, January 10, 2024

Saint-Herblain (France), January 10, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.

Key Points: 
  • Saint-Herblain (France), January 10, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
  • There is currently no approved chikungunya vaccine for children and Valneva’s vaccine IXCHIQ® is currently the only licensed chikungunya vaccine2 to address this unmet medical need in adults aged 18 years and older who are at increased risk of exposure to the virus.
  • Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, “This pediatric trial is extremely important.
  • Given the significant threat that chikungunya poses to individuals living in or traveling to endemic areas, it is crucial to make the vaccine accessible to all age groups.

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033 - Strong Growth by 2033 with a Focus on Treating Rare Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 27, 2023

The "Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033" has been added to ResearchAndMarkets.com's offering.
  • World revenue for the Antisense Oligonucleotide (ASO) Therapeutics Market is forecast to surpass US$6 billion in 2023, with strong revenue growth through to 2033.
  • Rare diseases, often referred to as orphan diseases, are characterized by their low prevalence in the population, making them less attractive for traditional drug development efforts.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antisense Oligonucleotide (ASO) Therapeutics prices and recent developments.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine

Retrieved on: 
Wednesday, October 11, 2023

EMERYVILLE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- October 11, 2023 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the presentation of results from three ongoing Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company’s CORAL program) at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA.

Key Points: 
  • Gritstone will present further follow up data from the CORAL-CEPI and CORAL-BOOST studies (most recent prior presentation in April 2023, press release ).
  • CORAL-BOOST (NCT05148962) is a Phase 1 study evaluating a samRNA-based COVID-19 vaccine candidate containing spike plus other viral targets in older adults ≥60 years of age (N = 40).
  • Broad T cell responses induced against Spike and non-Spike T cell epitopes included in the vaccine.
  • To view Gritstone’s IDWeek 2023 poster presentations, visit ir.gritstonebio.com/investors/events .

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

Retrieved on: 
Thursday, September 7, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230907759314/en/
    CIRION, a leading contract research organization has been operating global clinical trials over 30 years.
  • CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific.
  • Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically.
  • The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

Retrieved on: 
Wednesday, July 12, 2023

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety.

Key Points: 
  • This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety.
  • There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
  • Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE.
  • Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

KCAS Bioanalytical and Biomarker Services Announces Growth to Scientific Leadership Team

Retrieved on: 
Tuesday, April 25, 2023

In addition, he will continue his role as a key member of our current operations integration team and the Senior Leadership Team.

Key Points: 
  • In addition, he will continue his role as a key member of our current operations integration team and the Senior Leadership Team.
  • “I look forward to this new opportunity to expand further the footprint of the bioanalytical and Biomarkers fields at KCAS.
  • As Executive Director, Cheikh will be responsible for the strategic leadership and management oversight of our Biopharma Services division, positioning the company for continued growth.
  • In addition, he will be an integral member of our global Integration strategy and will continue to be a member of the Senior Leadership Team.

Global Healthcare Analytical Testing Services Market to 2027: Growing Focus on Analytical Testing of Biologics & Biosimilars and Increasing Number of Clinical Trials Drives Growth

Retrieved on: 
Tuesday, February 28, 2023

On the basis of type, the healthcare analytical testing services market is segmented into bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.

Key Points: 
  • On the basis of type, the healthcare analytical testing services market is segmented into bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.
  • Based on type, the bioanalytical testing services market is segmented into cell-based assays, virology testing, biomarker testing, immunogenicity & neutralizing antibody testing, pharmacokinetic testing, and other bioanalytical testing services.
  • The high growth rate of this segment is attributed demand for healthcare analytical testing services among medical device companies for validation testing services that aid with regulatoy approvals for device launch.
  • The healthcare analytical testing services market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, February 27, 2023

-- Successfully Raised Approximately $805 Million in Gross Proceeds in Two Follow-On Equity Offerings in 2022; $957.9 Million in Cash, Cash Equivalents and Investments as of December 31, 2022 --

Key Points: 
  • The FDA’s decision was based on positive topline results from the Phase 1/2 proof-of-concept study of VAX-24 in adults 18-64 years of age.
  • VAX-PG: Vaxcyte nominated a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, in the fourth quarter of 2022 and continues to progress the program.
  • The December 31, 2022, balance includes $651.6 million in net proceeds from the Company’s underwritten public offering completed in the fourth quarter of 2022.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2023, at 4:30 p.m.